title: Association between cytochrome P450 1A1 MspI polymorphism and endometrial cancer risk: a meta-analysis.
abstract: Many studies proposed that cytochrome P450 1A1 (CYP1A1) MspI polymorphism may be associated with endometrial cancer risk, but the findings from previous studies reported conflicting results. A meta-analysis of all relevant studies was performed to get a comprehensive assessment of the association between CYP1A1 MspI polymorphism and endometrial cancer risk. Eligible studies were searched in PubMed and China National Knowledge Infrastructure databases. The pooled odds ratios (ORs) with the corresponding 95 % confidence intervals (95 % CIs) were calculated to evaluate the association. Twelve studies with a total of 2,111 cases and 2,894 controls were finally included into the meta-analysis. Overall, meta-analysis of a total of 12 studies showed that there was no obvious association between CYP1A1 MspI polymorphism and endometrial cancer risk (ORC vs. T = 0.97, 95 % CI 0.77-1.22, P OR = 0.808; ORCC vs. TT = 1.00, 95 % CI 0.57-1.76, P OR = 0.994; ORCC vs. TT/TC = 0.88, 95 % CI 0.65-1.20, P OR = 0.425; ORCC/TC vs. TT = 0.98, 95 % CI 0.74-1.29, P OR = 0.861). Subgroup analyses by ethnicity further showed that there was no obvious association between CYP1A1 MspI polymorphism and endometrial cancer risk in both Caucasians and Asians. There was no obvious risk of publication bias. Therefore, the meta-analysis suggests that CYP1A1 MspI polymorphism is not associated with endometrial cancer risk.
authors.affiliation: Department of Gynecology, The Shilong People's Hospital of Dongguan, Dongguan, 523326, China, hlx19gz@yahoo.cn.
authors.forename: Linxiao
authors.initials: L
authors.lastname: Han
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Liu
authors.forename: Weiwei
authors.initials: W
authors.lastname: Cao
authors.forename: Xiuying
authors.initials: X
authors.lastname: Yuan
authors.forename: Cuifeng
authors.initials: C
authors.lastname: Li
mesh_terms: D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics*; D019003:Deoxyribonuclease HpaII / Q000737:chemistry; D016889:Endometrial Neoplasms / Q000201:enzymology / Q000235:genetics*; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D016017:Odds Ratio; D012150:Polymorphism, Restriction Fragment Length; D012307:Risk Factors
chemical_list: C569463:CYP1A1 protein, human; D019363:Cytochrome P-450 CYP1A1; D019003:Deoxyribonuclease HpaII
references.citation: Nat Rev Cancer. 2006 Dec;6(12):947-60
references.pmid: 17128211
references.citation: Cancer Res. 2009 Mar 1;69(5):1877-84
references.pmid: 19223546
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1311-20
references.pmid: 16985250
references.citation: Cancer Epidemiol. 2010 Jun;34(3):328-37
references.pmid: 20381444
references.citation: Pharmacogenomics J. 2006 May-Jun;6(3):189-93
references.pmid: 16402077
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):357-66
references.pmid: 15734958
references.citation: BMJ. 1998 Feb 7;316(7129):469; author reply 470-1
references.pmid: 9492685
references.citation: J Clin Oncol. 2010 Feb 10;28(5):788-92
references.pmid: 20065186
references.citation: Nat Rev Cancer. 2013 Jan;13(1):27-36
references.pmid: 23192231
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1220-6
references.pmid: 19164205
references.citation: Tumour Biol. 2012 Dec;33(6):2265-72
references.pmid: 22948778
references.citation: Br J Cancer. 1997;75(9):1385-8
references.pmid: 9155064
references.citation: Int J Gynecol Cancer. 2003 Nov-Dec;13(6):785-90
references.pmid: 14675315
references.citation: Adv Exp Med Biol. 2008;617:359-66
references.pmid: 18497059
references.citation: Cancer Causes Control. 2007 Dec;18(10):1123-30
references.pmid: 17717632
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: J Clin Oncol. 2011 Mar 1;29(7):832-8
references.pmid: 21263082
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Tumour Biol. 2013 Jun;34(3):1511-6
references.pmid: 23381648
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Tumour Biol. 2013 Feb;34(1):223-30
references.pmid: 23055196
references.citation: Nat Genet. 2011 May;43(5):451-4
references.pmid: 21499250
references.citation: Hypertension. 2010 Apr;55(4):1005-11
references.pmid: 20212268
references.citation: Cancer. 2008 May 1;112(9):1964-73
references.pmid: 18318428
references.citation: Oncol Res. 2010;18(7):343-7
references.pmid: 20377136
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120